{"id":510532,"date":"2021-07-07T16:08:56","date_gmt":"2021-07-07T20:08:56","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/codexis-earns-milestone-payment-from-glaxosmithkline\/"},"modified":"2021-07-07T16:08:56","modified_gmt":"2021-07-07T20:08:56","slug":"codexis-earns-milestone-payment-from-glaxosmithkline","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/codexis-earns-milestone-payment-from-glaxosmithkline\/","title":{"rendered":"Codexis Earns Milestone Payment from GlaxoSmithKline"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">REDWOOD CITY, Calif., July  07, 2021  (GLOBE NEWSWIRE) &#8212; Codexis, Inc. (Nasdaq: CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, announced it earned a significant milestone payment related to the licensing of its proprietary CodeEvolver\u00ae protein engineering platform technology to GlaxoSmithKline (GSK). This milestone marks the advancement of the commercialization of an enzyme, generated using CodeEvolver under the licensing agreement, that is engineered to improve a key step in the manufacturing process for a currently undisclosed drug. The milestone, which was expected in the second half of 2021, was recorded as revenue in the second quarter.<\/p>\n<p align=\"justify\">\u201cCodexis is proud that our CodeEvolver platform continues to offer robust value to GSK,\u201d said John Nicols, President and CEO of Codexis. \u201cAs our first platform licensing partner, it is gratifying to see the value of our relationship with GSK continue to grow. This milestone reinforces our confidence that CodeEvolver licensing backend economics will become a significant and growing long term revenue source as our platform partners &#8211; currently three of the world\u2019s leading pharmaceutical companies &#8211; continue to commercialize their CodeEvolver developed enzymes.\u201d<\/p>\n<p>\n        <strong>About Codexis<\/strong><br \/>\n        <br \/>Codexis is a leading enzyme engineering company leveraging its proprietary CodeEvolver\u00ae\u00a0platform to discover and develop novel, high performance enzymes and novel biotherapeutics. Codexis enzymes have applications in the sustainable manufacturing of pharmaceuticals, food, and industrial products; in the creation of the next generation of life science tools; and as gene therapy and biologic therapeutics. The Company\u2019s unique performance enzymes drive improvements such as: reduced energy usage, waste generation and capital requirements; higher yields; higher fidelity diagnostics; and more efficacious therapeutics. Codexis enzymes enable the promise of synthetic biology to improve the health of people and the planet. For more information, visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=lVeneA9kcpWAA4Bl6_IVGwz6pDbBA55JzAi8ald-kY3G5XeP4MoWKPUpKe72fPr66a0-LSPXlSenSbb3lsThrGRw1B_gURHsAyYqWyYMx9zy_NdZgVtV2JNPDvXMrQcs_8L6V3YEFeuZHVnK2vyoVGUJpWRdob1WaP1FSz7b_dk8bF0uMr5z0zs6j8fX4kr_WKm2tB70GQfrZH0XX1szMzyyWYcZETas8GgtyM4c7ChzqDAgkgF3FjGY-dDdbLn0_Pt-nN-TsmK3_6Diy1bpqBx5j-x5tCjIJ3FO_1WGuoz1Mq2gzkJkdTFXGhdGjxHsCfxh2oj95dx7rE1U-BywMiGaUB9oIzCYdhANBJfwGnqsvoLUs9bT3DI2IB0rvSQ82jc1MSVqnpRymTFOuIEK12L7qEIPoYrURaZYEZL0KjQ=\" rel=\"nofollow noopener\" target=\"_blank\">www.codexis.com<\/a>.<\/p>\n<p>\n        <strong>Forward-Looking Statements<\/strong>\n      <\/p>\n<p align=\"justify\">To the extent that statements contained in this press release are not descriptions of historical facts regarding Codexis, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. You should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties and other factors that are, in some cases, beyond Codexis\u2019 control and that could materially affect actual results. Factors that could materially affect actual results include, among others: Codexis\u2019 dependence on its licensees and collaborators; Codexis\u2019 dependence on a limited number of products and customers; and potential adverse effects to Codexis\u2019 business if its customers\u2019 products are not received well in the markets. Additional information about factors that could materially affect actual results can be found in Codexis\u2019 Annual Report on Form 10-K filed with the Securities and Exchange Commission (\u201cSEC\u201d) on March 1, 2021, and in Codexis\u2019 Quarterly Report on Form 10-Q filed with the SEC on May 7, 2021, including under the caption \u201cRisk Factors,\u201d and in Codexis\u2019 other periodic reports filed with the SEC. Codexis expressly disclaims any intent or obligation to update these forward-looking statements, except as required by law.<\/p>\n<p>\n        <strong>Investor Relations Contact:<\/strong><br \/>\n        <br \/>Argot Partners<br \/>Stephanie Marks\/Carrie McKim<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=imAssn80Fu0lk-rp_B30-ZsjFTyWcB06IWsLwBLS7T3ffSVoXmsgeyXiRSCN7n2nwGs8d8frJBtxhFJauwv6ADZEQq7CJyuDtin_osBbYmovl0HmqtDADUBJvIeEv8vT55jCEsbgpxf6RDZWRmIC1HXdw9fkUtt0bLWWv0uV42MjZXgVFVKrm_qVri0-2i8VZMVcSWyhhWrzFC0wqonRnG9DWEz6b683GIWaoSDq1cWfPP7JGUN9_JT5SwCFbvwwT4dpzxuJgPitoFnXeSArBw==\" rel=\"nofollow noopener\" target=\"_blank\">Codexis@argotpartners.com<\/a><br \/>(212) 600-1902<\/p>\n<p \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI3NjgxOCM0Mjg2ODY2IzIwMTY1MzQ=\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/1824aaa4-e463-41a4-a063-1363e4fc2bbd\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>REDWOOD CITY, Calif., July 07, 2021 (GLOBE NEWSWIRE) &#8212; Codexis, Inc. (Nasdaq: CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, announced it earned a significant milestone payment related to the licensing of its proprietary CodeEvolver\u00ae protein engineering platform technology to GlaxoSmithKline (GSK). This milestone marks the advancement of the commercialization of an enzyme, generated using CodeEvolver under the licensing agreement, that is engineered to improve a key step in the manufacturing process for a currently undisclosed drug. The milestone, which was expected in the second half of 2021, was recorded as revenue in the second quarter. \u201cCodexis is proud that our CodeEvolver platform continues to offer robust value to GSK,\u201d said John Nicols, President and CEO &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/codexis-earns-milestone-payment-from-glaxosmithkline\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Codexis Earns Milestone Payment from GlaxoSmithKline&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-510532","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Codexis Earns Milestone Payment from GlaxoSmithKline - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/codexis-earns-milestone-payment-from-glaxosmithkline\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Codexis Earns Milestone Payment from GlaxoSmithKline - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"REDWOOD CITY, Calif., July 07, 2021 (GLOBE NEWSWIRE) &#8212; Codexis, Inc. (Nasdaq: CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, announced it earned a significant milestone payment related to the licensing of its proprietary CodeEvolver\u00ae protein engineering platform technology to GlaxoSmithKline (GSK). This milestone marks the advancement of the commercialization of an enzyme, generated using CodeEvolver under the licensing agreement, that is engineered to improve a key step in the manufacturing process for a currently undisclosed drug. The milestone, which was expected in the second half of 2021, was recorded as revenue in the second quarter. \u201cCodexis is proud that our CodeEvolver platform continues to offer robust value to GSK,\u201d said John Nicols, President and CEO &hellip; Continue reading &quot;Codexis Earns Milestone Payment from GlaxoSmithKline&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/codexis-earns-milestone-payment-from-glaxosmithkline\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-07-07T20:08:56+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI3NjgxOCM0Mjg2ODY2IzIwMTY1MzQ=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/codexis-earns-milestone-payment-from-glaxosmithkline\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/codexis-earns-milestone-payment-from-glaxosmithkline\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Codexis Earns Milestone Payment from GlaxoSmithKline\",\"datePublished\":\"2021-07-07T20:08:56+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/codexis-earns-milestone-payment-from-glaxosmithkline\\\/\"},\"wordCount\":513,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/codexis-earns-milestone-payment-from-glaxosmithkline\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI3NjgxOCM0Mjg2ODY2IzIwMTY1MzQ=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/codexis-earns-milestone-payment-from-glaxosmithkline\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/codexis-earns-milestone-payment-from-glaxosmithkline\\\/\",\"name\":\"Codexis Earns Milestone Payment from GlaxoSmithKline - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/codexis-earns-milestone-payment-from-glaxosmithkline\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/codexis-earns-milestone-payment-from-glaxosmithkline\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI3NjgxOCM0Mjg2ODY2IzIwMTY1MzQ=\",\"datePublished\":\"2021-07-07T20:08:56+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/codexis-earns-milestone-payment-from-glaxosmithkline\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/codexis-earns-milestone-payment-from-glaxosmithkline\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/codexis-earns-milestone-payment-from-glaxosmithkline\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI3NjgxOCM0Mjg2ODY2IzIwMTY1MzQ=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI3NjgxOCM0Mjg2ODY2IzIwMTY1MzQ=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/codexis-earns-milestone-payment-from-glaxosmithkline\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Codexis Earns Milestone Payment from GlaxoSmithKline\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Codexis Earns Milestone Payment from GlaxoSmithKline - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/codexis-earns-milestone-payment-from-glaxosmithkline\/","og_locale":"en_US","og_type":"article","og_title":"Codexis Earns Milestone Payment from GlaxoSmithKline - Market Newsdesk","og_description":"REDWOOD CITY, Calif., July 07, 2021 (GLOBE NEWSWIRE) &#8212; Codexis, Inc. (Nasdaq: CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, announced it earned a significant milestone payment related to the licensing of its proprietary CodeEvolver\u00ae protein engineering platform technology to GlaxoSmithKline (GSK). This milestone marks the advancement of the commercialization of an enzyme, generated using CodeEvolver under the licensing agreement, that is engineered to improve a key step in the manufacturing process for a currently undisclosed drug. The milestone, which was expected in the second half of 2021, was recorded as revenue in the second quarter. \u201cCodexis is proud that our CodeEvolver platform continues to offer robust value to GSK,\u201d said John Nicols, President and CEO &hellip; Continue reading \"Codexis Earns Milestone Payment from GlaxoSmithKline\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/codexis-earns-milestone-payment-from-glaxosmithkline\/","og_site_name":"Market Newsdesk","article_published_time":"2021-07-07T20:08:56+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI3NjgxOCM0Mjg2ODY2IzIwMTY1MzQ=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/codexis-earns-milestone-payment-from-glaxosmithkline\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/codexis-earns-milestone-payment-from-glaxosmithkline\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Codexis Earns Milestone Payment from GlaxoSmithKline","datePublished":"2021-07-07T20:08:56+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/codexis-earns-milestone-payment-from-glaxosmithkline\/"},"wordCount":513,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/codexis-earns-milestone-payment-from-glaxosmithkline\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI3NjgxOCM0Mjg2ODY2IzIwMTY1MzQ=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/codexis-earns-milestone-payment-from-glaxosmithkline\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/codexis-earns-milestone-payment-from-glaxosmithkline\/","name":"Codexis Earns Milestone Payment from GlaxoSmithKline - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/codexis-earns-milestone-payment-from-glaxosmithkline\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/codexis-earns-milestone-payment-from-glaxosmithkline\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI3NjgxOCM0Mjg2ODY2IzIwMTY1MzQ=","datePublished":"2021-07-07T20:08:56+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/codexis-earns-milestone-payment-from-glaxosmithkline\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/codexis-earns-milestone-payment-from-glaxosmithkline\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/codexis-earns-milestone-payment-from-glaxosmithkline\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI3NjgxOCM0Mjg2ODY2IzIwMTY1MzQ=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI3NjgxOCM0Mjg2ODY2IzIwMTY1MzQ="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/codexis-earns-milestone-payment-from-glaxosmithkline\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Codexis Earns Milestone Payment from GlaxoSmithKline"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/510532","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=510532"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/510532\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=510532"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=510532"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=510532"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}